GSK-A1

Category	Hepatitis C Virus (HCV)
CAS	1416334-69-4
Description	GSK-A1 is a selective type III phosphatidylinositol 4-kinase PI4KA (PI4KIIIα) inhibitor with a pIC50 of 8.5-9.8. GSK-A1 inhibits PtdIns(4,5)P2 resynthesis with an IC50 of about 3 nM. GSK-A1 potently decreases the levels of PtdIns(4)P with a negligible effect on PtdIns(4,5)P2. GSK-A1 has the potential for anti-hepatitis C virus (HCV) research.

Quotation Now

Synonyms	GSK-A1\|1416334-69-4\|5-[2-amino-3-(4-morpholin-4-ylphenyl)benzimidazol-5-yl]-N-(2-fluorophenyl)-2-methoxypyridine-3-sulfonamide\|5-{2-amino-1-[4-(morpholin-4-yl)phenyl]-1H-benzimidazol-6-yl}-N-(2-fluorophenyl)-2-methoxypyridine-3-sulfonamide\|PI4KA inhibitor-A1\|A1;GSKA1\|SCHEMBL14247403\|BCP28055\|EX-A5297\|AKOS037643421\|ZINC144874408\|AC-36732\|AS-16345\|HY-125118\|CS-0089366\|A900427\|5-(2-Amino-1-(4-morpholinophenyl)-1H-benzimidazol-6-yl)-N-(2-fluorophenyl)-2-methoxypyridine-3-sulfonamide\|E4S
Molecular Weight	574.63
Molecular Formula	C29H27FN6O4S
Canonical SMILES	COC1=C(C=C(C=N1)C2=CC3=C(C=C2)N=C(N3C4=CC=C(C=C4)N5CCOCC5)N)S(=O)(=O)NC6=CC=CC=C6F
Purity	≥98%
Solubility	DMSO: 2 mg/ml
Appearance	Solid powder
Storage	Store at -20°C
Complexity	959
Exact Mass	574.17985270
Target	PI4K; HCV
XLogP3-AA	4